- Pipeline · Lixumistat (IM156)
One Asset.
Multiple Indications.
Lixumistat is ImmunoMet’s lead compound — a selective OxPhos inhibitor with a clean safety profile established across Phase 1 studies and active Phase 1b/2a clinical evidence in pancreatic cancer.
- Development Programme
Lixumistat (IM156) —
Completed & Ongoing Studies
Study
Indication
Status
Phase
Key Notes
Phase 1
NCT03272256
Advanced Solid Tumours
Complete
Done
Published: Janku et al., Inv New Drugs, 2022. Safety profile established. No DLTs.
Phase 1
Healthy Volunteers
PK / Food Effect
Complete
Done
No food effect. On-target activity confirmed. No DLTs.
Phase 1b/2a
NCT05497778
Pancreatic Cancer (PDAC)
Active · Enrolling
Active
MD Anderson. PI: Dr. Shubham Pant. 50% ORR, 80% DCR at RP2D. N=25.
Phase 1/2
GBM
Glioblastoma
IND Preparation
Planned
Window-of-Opportunity study + Phase 2. Glioblastoma Therapeutic Network engaged.
All study data verified from MASTER v4.pdf and ImmunoMet_Investor_Slides_202603_1.pdf. NCT numbers confirmed. GBM IND preparation confirmed.
- Interested in ImmunoMet?
Partnering or investing in lixumistat's development
ImmunoMet is currently raising to complete the PDAC study and initiate GBM studies. If you’re an investor or potential partner, get in touch.
